The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A‐PBX1: A 10‐year retrospective study

The clinical outcomes and genomic features of E2A‐PBX1 (TCF3‐PBX1)‐positive B‐cell acute lymphoblastic leukemia (B‐ALL) patients remain unclear. A total of 137 patients carrying E2A‐PBX1 among 3164 B‐ALL patients between 2009 and 2019 were retrospectively analyzed. The 5‐year overall survival (OS) a...

Full description

Saved in:
Bibliographic Details
Published in:American journal of hematology 2021-11, Vol.96 (11), p.1461-1471
Main Authors: Zhou, Biqi, Chu, Xinran, Tian, Hong, Liu, Tianhui, Liu, Hong, Gao, Wei, Chen, Suning, Hu, Shaoyan, Wu, Depei, Xu, Yang
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Adolescent
Adolescents
Adult
Basic Helix-Loop-Helix Transcription Factors - genetics
Cell cycle
Chemotherapy
Clinical outcomes
Clonal Evolution
DNA repair
Female
Gene deletion
Gene regulation
Genomics
Hematology
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Histocompatibility antigen HLA
Homeodomain Proteins - genetics
Humans
Immunotherapy, Adoptive
Leukemia
Lymphatic leukemia
Male
Medical prognosis
Minimal residual disease
Mutation
Neoplasm, Residual
Nerve growth factor
Oncogene Proteins, Fusion - genetics
p53 Protein
Patients
Pax5 protein
Phenotypes
Pre-B-Cell Leukemia Transcription Factor 1 - genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology
Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Prognosis
Remission
Retrospective Studies
Risk factors
Signal transduction
Stem cell transplantation
Survival Analysis
Teenagers
Transcription
Transcriptome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The clinical outcomes and genomic features of E2A‐PBX1 (TCF3‐PBX1)‐positive B‐cell acute lymphoblastic leukemia (B‐ALL) patients remain unclear. A total of 137 patients carrying E2A‐PBX1 among 3164 B‐ALL patients between 2009 and 2019 were retrospectively analyzed. The 5‐year overall survival (OS) and disease‐free survival (DFS) rates of the whole cohort were 68.6% and 61.0%, respectively. Age [DFS, p = 0.037; cumulative incidence of relapse (CIR), p = 0.005] and the level of minimal residual disease (MRD) after induction chemotherapy (OS, p = 0.020; DFS, p = 0.002; CIR, p = 0.006) were independent risk factors. In adolescents/adults, allogeneic hematopoietic stem cell transplantation (allo‐HSCT) at first complete remission (CR1) significantly improved the 5‐year prognosis (OS, p 
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.26324